Methylnaltrexone: a novel approach for the management of opioid-induced constipation in patients with advanced illness

References

• Cherny N, Ripamonti C, Pereira J et al. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J. Clin. Oncol.19, 2542–2554 (2001).
   PubMed Web of Science ®Google Scholar
• Mehendale SR, Yuan CS. Opioid-induced gastrointestinal dysfunction. Dig. Dis.24, 105–112 (2006).
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Thomas J, Moehl Boatwright ML et al. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study. J. Pain Symptom Manage.35, 458–468 (2008).
   PubMed Web of Science ®Google Scholar
• Portenoy RK. Constipation in the cancer patient: causes and management. Med. Clin. North Am.71, 303–311 (1987).
   PubMed Web of Science ®Google Scholar
• Glare P, Lickiss JN. Unrecognized constipation in patients with advanced cancer: a recipe for therapeutic disaster. J. Pain Symptom Manage.7, 369–371 (1992).
   PubMed Web of Science ®Google Scholar
• Longstreth GF, Thompson WG, Chey WD et al. Functional bowel disorders. Gastroenterology130, 1480–1491 (2006).
   PubMed Web of Science ®Google Scholar
• Kromer W. Endogenous and exogenous opioids in the control of gastrointestinal motility and secretion. Pharmacol. Rev.40, 121–162 (1988).
   PubMed Web of Science ®Google Scholar
• Collett BJ. Opioid tolerance: the clinical perspective. Br. J. Anaesth.81, 58–68 (1998).
   PubMed Web of Science ®Google Scholar
• Thomas JR, Von Gunten CF. Management of constipation in patients with cancer. Support Cancer Ther.2, 47–51 (2004).
   PubMedGoogle Scholar
• Cherny NI. The pharmacological management of cancer pain. Eur. J. Cancer.37(Suppl. 7), S265–S278 (2001).
   Google Scholar
• Herndon CM, Jackson KC, Hallin PA. Management of opioid-induced gastrointestinal effects in patients receiving palliative care. Pharmacotherapy22, 240–250 (2002).
   PubMed Web of Science ®Google Scholar
• Yuan CS. Methylnaltrexone mechanisms of action and effects on opioid bowel dysfunction and other opioid adverse effects. Ann. Pharmacother.41, 984–993 (2007).
   PubMed Web of Science ®Google Scholar
• Wood JD, Galligan JJ. Function of opioids in the enteric nervous system. Neurogastroenterology Motil.16(Suppl. 2), 17–28 (2004).
   PubMed Web of Science ®Google Scholar
• Galligan JJ, Vanner S. Basic and clinical pharmacology of new motility promoting agents. Neurogastroenterol. Motil.17, 643–653 (2005).
   PubMed Web of Science ®Google Scholar
• De Schepper HU, Cremonini F, Park MI et al. Opioids and the gut: pharmacology and current clinical experience. Neurogastroenterol. Motil.16, 383–394 (2004).
   PubMed Web of Science ®Google Scholar
• Choi YS, Billings JA. Opioid antagonists: a review of their role in palliative care, focusing on use in opioid-related constipation. J. Pain Symptom Manage.24, 71–90 (2002).
   PubMed Web of Science ®Google Scholar
• Panchal SJ, Muller-Schwefe P, Wurzelmann JI. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int. J. Clin. Pract.61, 1181–1187 (2007).
   PubMed Web of Science ®Google Scholar
• Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am. J. Surg.182, S11–S18 (2001).
   PubMed Web of Science ®Google Scholar
• Berde C, Nurko S. Opioid side effects – mechanism-based therapy. N. Engl. J. Med.358, 2400–2402 (2008).
   PubMed Web of Science ®Google Scholar
• Miles CL, Fellowes D, Goodman ML et al. Laxatives for the management of constipation in palliative care patients. Cochrane Database Syst. Rev.4, CD003448 (2006).
   Google Scholar
• Liu M, Wittbrodt E. Low-dose oral naloxone reverses opioid-induced constipation and analgesia. J. Pain Symptom Manage.23, 48–53 (2002).
   PubMed Web of Science ®Google Scholar
• Sykes NP. Oral naloxone in opioid-associated constipation. Lancet337, 1475 (1991).
   PubMed Web of Science ®Google Scholar
• Sykes NP. An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliat. Med.10, 135–144 (1996).
   PubMed Web of Science ®Google Scholar
• McNicol ED, Boyce D, Schumann R et al. µ-opioid antagonists for opioid-induced bowel dysfunction. Cochrane Database Syst. Rev.2, CD006332 (2008).
   Google Scholar
• Joint Formulary Committee. British National Formulary (57th Edition). British Medical Association and Royal Pharmaceutical Society of Great Britain, London, UK (2009).
   Google Scholar
• GlaxoSmithKline. Alvimopan: summary of product characteristics.
   Google Scholar
• Paulson DM, Kennedy DT, Donovick RA et al. Alvimopan: an oral, peripherally acting, µ-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction – a 21 day treatment-randomized clinical trial. J. Pain6, 184–192 (2005).
   PubMed Web of Science ®Google Scholar
• Webster L, Jansen JP, Peppin J et al. Alvimopan, a peripherally acting µ-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain. Pain137, 428–440 (2008).
   PubMed Web of Science ®Google Scholar
• Saad R, Chey WD. Lubiprostone for chronic idiopathic constipation and irritable bowel syndrome with constipation. Expert Rev. Gastroenterol. Hepatol.2, 497–508 (2008).
   PubMedGoogle Scholar
• Johanson JF, Morton D, Geenen J et al. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am. J. Gastroenterol.103, 170–177 (2008).
   PubMed Web of Science ®Google Scholar
• Sykes NP. The relationship between opioid use and laxative use in terminally ill cancer patients. Palliat. Med.12, 375–382 (1998).
   PubMed Web of Science ®Google Scholar
• Thomas J, Karver S, Cooney GA et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N. Engl. J. Med.358, 2332–2343 (2008).
   PubMed Web of Science ®Google Scholar
• Campora E, Merlini L, Pace M et al. The incidence of narcotic-induced emesis. J. Pain Symptom Manage.6, 428–430 (1991).
   PubMed Web of Science ®Google Scholar
• Aparasu R, McCoy RA, Weber C et al. Opioid-induced emesis among hospitalized nonsurgical patients: effect on pain and quality of life. J. Pain Symptom Manage.18, 280–288 (1999).
   PubMed Web of Science ®Google Scholar
• Foss JF, Yuan CS, Roizen MF et al. Prevention of apomorphine- or cisplatin-induced emesis in the dog by a combination of methylnaltrexone and morphine. Cancer Chemother. Pharmacol.42, 287–291 (1998).
   PubMed Web of Science ®Google Scholar
• Foss JF, Bass AS, Goldberg LI. Dose-related antagonism of the emetic effect of morphine by methylnaltrexone in dogs. J. Clin. Pharmacol.33, 747–751 (1993).
   PubMed Web of Science ®Google Scholar
• Moerman I, Franck P, Camu F. Evaluation of methylnaltrexone for the reduction of postoperative vomiting and nausea incidences. Acta Anaesthesiol. Belg.46, 127–132 (1995).
   PubMedGoogle Scholar
• Foss JF, O’Connor MF, Yuan CS et al. Safety and tolerance of methylnaltrexone in healthy humans: a randomized, placebo-controlled, intravenous, ascending-dose, pharmacokinetic study. J. Clin. Pharmacol.37, 25–30 (1997).
   PubMed Web of Science ®Google Scholar
• Yuan CS, Foss JF, O’Connor M et al. Methylnaltrexone prevents morphine-induced delay in oral–cecal transit time without affecting analgesia: a double-blind randomized placebo-controlled trial. Clin. Pharmacol. Ther.59, 469–475 (1996).
   PubMed Web of Science ®Google Scholar
• Yuan CS, Foss JF, O’Connor M et al. Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial. JAMA283, 367–372 (2000).
   PubMed Web of Science ®Google Scholar
• Viscusi ER, Rathmell JP, Fichera A et al. Methylnaltrexone bromide administered postoperatively to patients following segmental colectomy may accelerate bowel recovery and hospital discharge without affecting opioid analgesia. Presented at: Gastrointestinal Cancers Symposium 2007. Orlando, FL, USA, 19–21 January 2007.
   Google Scholar
• Slatkin N, Thomas J, Lipman AG et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. J. Support. Oncol.7, 39–46 (2009).
   PubMedGoogle Scholar
• Yuan CS, Foss JF, Osinski J et al. The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral–cecal transit time. Clin. Pharmacol. Ther.61, 467–475 (1997).
   PubMed Web of Science ®Google Scholar
• Kraft MD. Methylnaltrexone, a new peripherally acting µ-opioid receptor antagonist being evaluated for the treatment of postoperative ileus. Expert Opin. Investig. Drugs17, 1365–1377 (2008).
   PubMed Web of Science ®Google Scholar
• Rosow CE, Gomery P, Chen TY et al. Reversal of opioid-induced bladder dysfunction by intravenous naloxone and methylnaltrexone. Clin. Pharmacol. Ther.82, 48–53 (2007).
   PubMed Web of Science ®Google Scholar
• Yuan CS, Foss JF, O’Connor M et al. Efficacy of orally administered methylnaltrexone in decreasing subjective effects after intravenous morphine. Drug Alcohol Depend.52, 161–165 (1998).
   PubMed Web of Science ®Google Scholar
• Ho WZ, Guo CJ, Yuan CS et al. Methylnaltrexone antagonizes opioid-mediated enhancement of HIV infection of human blood mononuclear phagocytes. J. Pharmacol. Exp. Ther.307, 1158–1162 (2003).
   PubMed Web of Science ®Google Scholar